Role of rho kinase signal pathway in inflammatory bowel disease

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3089-3097

  Huang, Yuan ^a   Xiao, Shiyu ^a   Jiang, Quanhang ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

IBD; Intestinal barrier; Intestinal fibrosis; Rho Rho kinase

Indexed keywords

ALPHA CATENIN; DESMOGLEIN; DESMOPLAKIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; MYOSIN; MYOSIN LIGHT CHAIN; RHO KINASE; UVOMORULIN;

ARTICLE; CELL JUNCTION; CROHN DISEASE; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINAL FIBROSIS; INTESTINE INJURY; MORBIDITY; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 84929192344     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Van Aelst L and D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11: 2295-2322.
2. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Embo J 1996; 15: 2208-2216.
3. Boguski MS and McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654.
4. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M and Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-983.
5. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y and Shimokawa H. Crucial role of rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol 2014; 34: 1260-1271.
6. Masamune A, Kikuta K, Satoh M, Satoh K and Shimosegawa T. Rho kinase inhibitors block activation of pancreatic stellate cells. Br J Pharmacol 2003; 140: 1292-1302.
7. Duong-Quy S, Bei Y, Liu Z and Dinh-Xuan AT. Role of Rho-kinase and its inhibitors in pulmonary hypertension. Pharmacol Ther 2013; 137: 352-364.
8. Farhadi A, Banan A, Fields J and Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003; 18: 479-497.
9. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809.
10. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013; 70: 631-659.
11. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S and Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993; 123: 1777-1788.
12. Furuse M, Fujita K, Hiiragi T, Fujimoto K and Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998; 141: 1539-1550.
13. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D and Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998; 142: 117-127.
14. Gonzalez-Mariscal L, Betanzos A, Nava P and Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003; 81: 1-44.
15. Turner JR, Rill BK, Carlson SL, Carnes D, Kerner R, Mrsny RJ and Madara JL. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997; 273: C1378-1385.
16. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169: 1901-1909.
17. Walsh SV, Hopkins AM, Chen J, Narumiya S, Parkos CA and Nusrat A. Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia. Gastroenterology 2001; 121: 566-579.
18. Clayburgh DR, Shen L and Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004; 84: 282-291.
19. Mankertz J and Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007; 23: 379-383.
20. Laukoetter MG, Nava P and Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14: 401-407.
21. Merga Y, Campbell BJ and Rhodes JM. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis 2014; 32: 475-483.
22. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermuller N, Otto HF and Autschbach F. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 2001; 281: G216-228.
23. Braegger CP, Nicholls S, Murch SH, Stephens S and MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
24. Murch SH, Braegger CP, Walker-Smith JA and MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-1709.
25. Bouma G and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533.
26. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I and Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s disease. Int J Colorectal Dis 2004; 19: 308-315.
27. Ko JK and Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des 2014; 20: 1082-1096.
28. Al-Sadi RM and Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007; 178: 4641-4649.
29. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS and Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638.
30. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burgel N, Fromm M, Zeitz M, Fuss I, Strober W and Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550-564.
31. Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque SS, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza GR and MacDonald TT. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 2014; 44: 370-385.
32. Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, Parkos CA and Nusrat A. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 2005; 16: 5040-5052.
33. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 6164-6172.
34. Segain JP, D Raingeard de la Bletiere , Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP and Loirand G. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn’s disease and experimental colitis. Gastroenterology 2003; 124: 1180-1187.
35. Mihaescu A, Santen S, Jeppsson B and Thorlacius H. Rho kinase signalling mediates radiation-induced inflammation and intestinal barrier dysfunction. Br J Surg 2011; 98: 124-131.
36. Burke JP, Mulsow JJ, O’Keane C, Docherty NG, Watson RW and O’Connell PR. Fibrogenesis in Crohn’s disease. Am J Gastroenterol 2007; 102: 439-448.
37. Speca S, Giusti I, Rieder F and Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012; 18: 3635-3661.
38. Gordon IO, Agrawal N, Goldblum JR, Fiocchi C and Rieder F. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis 2014; 20: 2198-2206.
39. Li C and Kuemmerle JF. Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm Bowel Dis 2014; 20: 1250-1258.
40. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM and O’Connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn’s disease. Br J Surg 2006; 93: 1290-1296.
41. Gunther U, Bateman AC, Beattie RM, Bauer M, MacDonald TT and Kaskas BA. Connective tissue growth factor expression is increased in collagenous colitis and coeliac disease. Histopathology 2010; 57: 427-435.
42. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R and Gendre JP. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002; 8: 244-250.
43. Schram K, Ganguly R, No EK, Fang X, Thong FS and Sweeney G. Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to enhanced cell migration. Endocrinology 2011; 152: 2037-2047.
44. McKaig BC, McWilliams D, Watson SA and Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003; 162: 1355-1360.
45. Chidlow JH Jr, Shukla D, Grisham MB and Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293: G5-G18.
46. Lawrance IC, Maxwell L and Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 226-236.
47. Bourgier C, Haydont V, Milliat F, Francois A, Holler V, Lasser P, Bourhis J, Mathe D and Vozenin-Brotons MC. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005; 54: 336-343.
48. Hoj JP, Davis JA, Fullmer KE, Morrell DJ, Saguibo NE, Schuler JT, Tuttle KJ and Hansen MD. Cellular contractility changes are sufficient to drive epithelial scattering. Exp Cell Res 2014; 326: 187-200.
49. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D and Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006; 103: 13180-13185.
50. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
51. Xu J, Lamouille S and Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
52. McKaig BC, Hughes K, Tighe PJ and Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C172-182.
53. Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M and Kalluri R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.